Granulomatöse rosazeaartiges Exanthem unter Tofacitinib

Translated title of the contribution: Granulomatous rosacea-like dermatitis under therapy with tofacitinib

Kristina Neumann*, Patrick Terheyden, Diamant Thaçi

*Corresponding author for this work


The case of a 32-year-old female with ulcerative colitis who developed severe papulopustular dermatitis while undergoing treatment with the Janus kinase (JAK) inhibitor tofacitinib. Despite intensive topical therapy, treatment with oral corticosteroids and oral doxycycline was unable to achieve sufficient improvement. Hence, tofacitinib treatment needed to be discontinued. It is well known that the class of JAK inhibitors can cause infectious and allergic cutaneous side effects. However, sterile papulopustular dermatitis as a side-effect has rarely been reported to date.

Translated title of the contributionGranulomatous rosacea-like dermatitis under therapy with tofacitinib
Original languageGerman
Publication statusPublished - 2021

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)


Dive into the research topics of 'Granulomatous rosacea-like dermatitis under therapy with tofacitinib'. Together they form a unique fingerprint.

Cite this